NCT01148953View on ClinicalTrials.gov

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions
Transthyretin Mediated Amyloidosis (ATTR)
Interventions
DRUG

ALN-TTR01

Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (4)

94275

Clinical Site, Le Kremlin-Bicêtre

4099-001

Clinical Site, Porto

SE 901 85

Clinical Site, Umeå

SE1 1YR

Clinical Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY